多黏菌素B静脉联合雾化吸入治疗多重耐药革兰阴性菌肺炎的临床研究
该观察性研究纳入45例ICU多重耐药G-菌肺炎患者,2020年1-4月25例接受多黏菌素B单用静脉滴注(首剂2.0 mg/kg,后续1.25 mg/kg,每12小时一次),5-10月20例接受静脉滴注联合雾化吸入(25 mg每12小时一次,先吸痰后雾化)。联合组总细菌清除率(70.0% vs 40.0%)和总临床有效率(75.0% vs 40.0%)均显著高于常规组,体温恢复时间和细菌清除时间显著缩短,治疗后PCT显著降低,肾毒性发生率无显著差异。
要点
- 联合组总细菌清除率70.0% vs 常规组40.0%,总临床有效率75.0% vs 40.0%,均P<0.05。
- 联合组体温恢复时间6.0±3.9天 vs 10.2±7.3天,细菌清除时间6.1±5.2天 vs 11.5±6.8天,均P<0.05。
- 联合组治疗后PCT显著低于治疗前及常规组治疗后(0.27 vs 0.85 μg/L,P<0.01)。
- 联合组肾毒性发生率5.0% vs 常规组4.0%,差异无统计学意义(P>0.05)。
- 雾化前需先吸净气道痰液再喷雾,雾化剂量为25 mg每12小时一次。
适用人群与场景
- ICU收治的多重耐药革兰阴性菌肺炎患者,痰培养结果为鲍曼不动杆菌、肺炎克雷伯菌、铜绿假单胞菌或阴沟肠杆菌。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 常规组:多黏菌素B静脉滴注,首剂2.0 mg/kg,后续1.25 mg/kg,每12小时一次。
- 联合组:在静脉滴注基础上加用雾化吸入多黏菌素B 25 mg,每12小时一次,雾化前先吸净气道痰液再喷雾。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 观察性研究,单中心(福建医科大学附属协和医院ICU),2020年1-10月,共45例多重耐药G-菌肺炎患者;常规组25例(2020年1-4月,单用静脉滴注),联合组20例(2020年5-10月,静脉滴注联合雾化吸入)。
- 两组痰培养结果分布无显著差异(P>0.05):常规组鲍曼不动杆菌13例、肺炎克雷伯菌5例、铜绿假单胞菌6例、阴沟肠杆菌1例;联合组鲍曼不动杆菌5例、肺炎克雷伯菌9例、铜绿假单胞菌6例。
- 联合组总细菌清除率显著高于常规组(70.0% vs 40.0%,P<0.05);总临床有效率显著高于常规组(75.0% vs 40.0%,P<0.05)。
- 联合组体温恢复时间(6.0±3.9天 vs 10.2±7.3天)和细菌清除时间(6.1±5.2天 vs 11.5±6.8天)均显著短于常规组(均P<0.05)。
- 治疗前两组血清PCT无显著差异;常规组治疗前后PCT无显著差异[0.85(0.44, 2.87)vs 1.43(0.76, 5.30)μg/L,P>0.05];联合组治疗后PCT显著低于治疗前[0.27(0.10, 0.70)vs 0.91(0.32, 3.53)μg/L,P<0.05],且显著低于常规组治疗后[0.27(0.10, 0.70)vs 0.85(0.44, 2.87)μg/L,P<0.01]。
- 联合组与常规组肾毒性发生率无显著差异(5.0% vs 4.0%,P>0.05)。
证据类型、等级与局限
- 观察性研究(非随机、历史对照),单中心,样本量小(45例),分组基于不同时间段,存在时间偏倚和选择偏倚可能;原文未提及证据等级或推荐强度。
对床旁实践的改变
- 对ICU多重耐药G-菌肺炎患者,在静脉使用多黏菌素B基础上可考虑联合雾化吸入(25 mg每12小时一次,先吸痰后雾化),以提高细菌清除率和临床有效率、缩短体温恢复和细菌清除时间,且不增加肾毒性风险;但证据来自单中心小样本观察性研究,需前瞻性验证。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the efficacy of intravenous combined with aerosol inhalation of polymyxin B for the treatment of pneumonia caused by multidrug-resistant Gram-negative (G-) bacteria.
METHODS: A observational study was conducted. The clinical data of 45 patients with pneumonia due to multidrug-resistant G- bacteria admitted to intensive care unit of Fujian Medical University Union Hospital from January to October in 2020 were analyzed. According to the different use methods of polymyxin B, 25 patients who received single intravenous drip (the first dose was 2.0 mg/kg, then 1.25 mg/kg, once every 12 hours) from January to April in 2020 were enrolled in the routine group, and 20 patients who received intravenous drip combined with aerosol inhalation (25 mg once every 12 hours, sputum in the airway was sucked and then sprayed aerosol) from May to October in 2020 were enrolled in the combination group. After the treatment course of polymyxin B, the total bacterial clearance rate, total clinical efficiency rate, recovery time of body temperature, time of bacterial clearance and the change of serum procalcitonin (PCT) level before and after treatment were compared between the two groups. Moreover, the incidence of adverse reactions during treatment in the two groups was observed.
RESULTS: The results of sputum culture in the routine group were Acinetobacter baumannii in 13 patients, Klebsiella pneumoniae in 5 patients, Pseudomonas aeruginosa in 6 patients, Enterobacter cloacae in 1 patient; the sputum culture results of the combination group showed that there were 5 patients of Acinetobacter baumannii, 9 Klebsiella pneumoniae and 6 Pseudomonas aeruginosa. There was no significant difference in the results of sputum culture between the two groups (P > 0.05). The total bacterial clearance rate and the total clinical efficiency rate of the combination group were significantly higher than those in the routine group (total bacterial clearance rate: 70.0% vs. 40.0%, total clinical efficiency rate: 75.0% vs. 40.0%, both P < 0.05). The recovery time of body temperature and the time of bacterial clearance of the combination group were significantly shorter than those in the routine group [recovery time of body temperature (days): 6.0±3.9 vs. 10.2±7.3, time of bacterial clearance (days): 6.1±5.2 vs. 11.5±6.8, both P < 0.05]. No significant difference was found in serum PCT level before treatment between the two group. There was no significant difference in serum PCT level before and after treatment in the routine group [μg/L: 0.85 (0.44, 2.87) vs. 1.43 (0.76, 5.30), P > 0.05]. The serum PCT level after treatment in the combination group was significantly lower than that before treatment [μg/L: 0.27 (0.10, 0.70) vs. 0.91 (0.32, 3.53), P < 0.05], and it was significantly lower than that in the routine group [μg/L: 0.27 (0.10, 0.70) vs. 0.85 (0.44, 2.87), P < 0.01]. The incidence of renal toxicity of polymyxin B between the combination group and the routine group was not significantly different (5.0% vs. 4.0%, P > 0.05).
CONCLUSIONS: The efficacy of intravenous combined with aerosol inhalation of polymyxin B for the treatment of pneumonia due to multidrug-resistant G- bacteria is better than that of intravenous drip of polymyxin B only. The aerosolized polymyxin B will not increase the risk of renal injury.
参考来源
- Zhou L, Li C, Weng Q, et al. [Clinical study on intravenous combined with aerosol inhalation of polymyxin B for the treatment of pneumonia caused by multidrug-resistant Gram-negative bacteria]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 34053483. doi:10.3760/cma.j.cn121430-20201215-00753
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。